Cell:模拟病毒感染带来癌症新疗法

2015-09-06 佚名 生物谷

近日,发表于国际杂志Cell上的一篇研究论文中,来自玛嘉烈公主癌症中心(Princess Margaret Cancer Centre)等处的研究人员通过对结直肠癌干细胞进行靶向研究阐明了一种模拟病毒的新机制,这或可潜在诱发免疫反应来抵御类似于感染引发的癌症。研究者De Carvalho说道,通过模拟病毒感染或许就可以诱骗机体免疫系统“看见”癌细胞,并且将癌细胞视作感染,进而就可以帮助清除癌细胞,

近日,发表于国际杂志Cell上的一篇研究论文中,来自玛嘉烈公主癌症中心(Princess Margaret Cancer Centre)等处的研究人员通过对结直肠癌干细胞进行靶向研究阐明了一种模拟病毒的新机制,这或可潜在诱发免疫反应来抵御类似于感染引发的癌症

研究者De Carvalho说道,通过模拟病毒感染或许就可以诱骗机体免疫系统“看见”癌细胞,并且将癌细胞视作感染,进而就可以帮助清除癌细胞,研究发现,病毒的这种模仿或许就可以提供一种可行的抗肿瘤策略;当前结直肠癌大约在50%的患者机体中都会复发,而且是三大癌症相关死亡的主要原因之一。

在临床前实验中,研究者对人类的结直肠癌细胞进行了复制,并且利用生物信息学技术分析发现,低剂量的化疗药物地西他滨可以通过诱导病毒模仿来靶向作用癌症干细胞。地西他滨是美国FDA批准的用于治疗骨髓增生异常综合征及白血病的药物,而且该药物在临床中还可以用于治疗多种类型的实体瘤,比如结直肠癌等,研究者表示,该药物可以激活一种识别病毒的通路。

本文研究中研究者发现了一种开启结直肠癌干细胞抗病毒反应的开关,而且研究者还指出,药物地西他滨可以诱导一种抗病毒反应,这种反应具有高度的免疫原性,或许可以被用于结合其它制剂来进行免疫疗法,即通过增强个体机体抵御疾病的天然防御能力来提供强大的个体化疗法,下一步研究者将开启临床试验来寻找是否靶向作用结直肠癌干细胞可以提供一种持久的治疗效力。

原文出处:

Roulois D1, Loo Yau H2,et al.DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.Cell.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2016-02-27 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2015-10-25 hlycom3356

    这篇文章写得非常好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2015-10-25 hlycom3356

    这篇文章写得非常好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2015-10-25 hlycom3356

    这篇文章写得非常好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2015-10-25 hlycom3356

    这篇文章写得非常好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869202, encodeId=b7ea1869202d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Jul 13 16:57:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959457, encodeId=1295195945e8e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 27 18:57:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41222, encodeId=db354122227, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41223, encodeId=eb674122334, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41224, encodeId=14344122426, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41225, encodeId=cab54122568, content=这篇文章写得非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 25 22:51:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554455, encodeId=cf4215544556a, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Mon Sep 07 23:57:00 CST 2015, time=2015-09-07, status=1, ipAttribution=)]
    2015-09-07 kcb074

相关资讯

Science:一滴血检测病毒感染史

霍华德休斯医学研究所(HHMI)的研究人员开发了一项新的技术,使人们有可能通过一滴血来检测目前和曾经任何已知人类病毒的感染情况。这个方法称为VirScan,是一种有效的测试病毒感染的替代诊断方法。文章发表在最新一期的Science杂志上。VirScan工作原理是筛查血液中存在的针对任何206种已知感染人类的病毒的抗体。我们的免疫系统在检测到病毒首次入侵的时候,会产生病原体特异性抗体,即使病毒感染清

Nat Med:治疗慢性病毒感染有新招

近日,来自美国的科学家在著名国际期刊nature medicine在线发表了他们的最新研究进展,他们发现慢性病毒感染如HIV等会导致细胞毒性T淋巴细胞功能衰退,在这个过程中前列腺素E2(PGE2)相关信号通路发挥了重要促进作用,因此,抑制PEG2或是治疗慢性病毒感染的一种有效手段。 目前,世界上有超过10%的人口正遭受HIV,HCV和HBV等慢性病毒感染的折磨,这几种疾病均可能引发严重并发症甚至死

Scientific reports:使用可卡因会增加HIV感染风险

近日,来自美国加州大学洛杉矶分校的研究人员提供了进一步的证据证明使用可卡因会干扰身体的免疫系统,导致使用者更易受到HIV病毒感染。 在这项最近发表在国际学术期刊scientific reports上的研究中,研究人员利用一种人源化小鼠模型研究了可卡因对免疫系统的影响,这种人源化小鼠模型是经过基因工程改造的,具有与人类类似的免疫系统。他们发现使用可卡因会导致使用者更容易感染HIV病毒。 &n

小知识:诺如病毒,腹泻爆发的常见“肇事者”

近日有报道称,广州一所学校接连数百名学生出现呕吐、腹泻、发烧等症状,广州疾控中心确定为诺如病毒感染性腹泻事件。一时间“诺如”成了“登革热”后广州的又一流行词。但这个罪魁祸首诺如病毒是什么呢? 诺如病毒:非细菌性腹泻的主要原因之一 诺如病毒(Norovirus,NV)是一组杯状病毒科的病毒,以前也称之为“诺瓦克样病毒”,是一组形态相似、抗原性略有不同的病毒颗粒。诺瓦

Cell. Host microbe: 病毒感染竟然促进伤口愈合

人体的大部分组织,器官都被表皮细胞所覆盖。表皮细胞对于人体免受外界环境的刺激具有十分重要的"屏障"作用。然而,表皮细胞并不是永生化的,它的更新换代必须受到严格的调控才能保证内部组织器官的安全。尤其是当病原体通过伤口进行感染的时候,表皮细胞需要找到合适的方式尽快愈合以降低恶化程度。       I型干扰素是宿主抗病毒免疫过程中主要的效应分子,根据这一特性,I

小心!诺如病毒高发期 北京已报告807病例

针对近期不少成人、儿童被“诺如病毒”感染,北京市疾控中心表示,北京仍处于诺如病毒感染高发期。2014年,北京共报告807例诺如病毒病例,发现聚集性病例39起,涉23所幼儿园和15所小学、1所大学。 市疾控中心表示,学校、幼儿园如发生诺如病毒感染聚集性疫情,学生症状消失后3天方可复课。学校最后一例病例出现后3天无新发病例方可解除疫情措施,期间学校及托幼机构不应组织外出聚会及开展大型活动。